纽约大学医学院2021年7月21日在biorxiv上发表了题为“Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants”研究，分析了不同疫苗接种者和康复者血清对不同新冠病毒突变株的中和效力变化。

    这项研究覆盖率多种重要变异体，包括Beta、Delta、Delta plus 和Lambda。研究结果表明强生疫苗对这些变异体的中和效力较低（IC₅₀小于50）。

Comparison of neutralization titers of variant spike protein pseudotyped viruses by convalescent sera, antibodies elicited by BNT162b2, mRNA-1273, Ad26.COV2.S.

四种血清的中和效力：

康复者血清面对D614G、Alpha、Beta、Delta、Delta plus 和Lambda的中和抗体滴度分别为：346、305、71、78、105和105；

辉瑞疫苗接种者血清的中和抗体滴度分别为：695、626、114、191、253和164；

Moderna疫苗接种者血清的中和抗体滴度分别为：833、722、182、207、250和229；

强生疫苗接种者血清的中和抗体滴度分别为：221、232、33、30、41和36。

以上转载自庄时利和微博——庄医生的疫情笔记。

不同疫苗接种者血清抗体在同一实验室的检测结果，成为大家关注的重点。

参考文献：doi: https://doi.org/10.1101/2021.07.19.452771  

    2021年7月15日香港大学研究团队在Lancet Microbe发表了题为“Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19”的通讯文章。研究者采用了4种不同方法比较两种COVID-19疫苗（辉瑞mRNA疫苗和科兴灭活疫苗）接种者血清的抗体滴度，包括中和抗体水平，实验结果见下图。

（论文附图 PRNT50: 269 vs. 27；PRNT90: 113 vs. 8.4）

根据这组数据，特别需要提醒的是：接种疫苗，一定要完成两剂接种。

准确的数据，是建立科学防疫、决策者运筹帷幄的基础。

更多SARS-CoV-2 临床研究论文解读，可关注“Hanson临床科研”公众号。

    原文摘录：“We report here comparative data on SARS-CoV-2 vaccine immunogenicity in health-care workers in Hong Kong who received either the BNT162b2 vaccine (Comirnaty; Fosun–BioNTech) or the inactivated virus (vero cell) vaccine (Coronavac; Sinovac). We collected blood samples before vaccination, before the second dose, and 21–35 days after the second dose. We tested the samples for antibodies to SARS-CoV-2 using an ELISA to detect antibodies that bind to the receptor binding domain of the spike protein, testing ELISA-positive samples for neutralising antibodies with a surrogate virus neutralisation (sVNT) assay, and then a plaque reduction neutralisation test (PRNT) with live SARS-CoV-2 virus.

...

    In health-care workers who received the BNT162b2 vaccine, antibody concentrations measured by ELISA and sVNT rose substantially after the first dose and then rose again after the second dose of vaccination. In a subset of 12 participants for whom we also had PRNT results, after the second dose the geometric mean PRNT₅₀ titre was 269 and the geometric mean PRNT₉₀ titre was 113.   In contrast, the health-care workers who received the inactivated vaccine had low antibody concentrations by ELISA and sVNT after the first dose, rising to moderate concentrations after the second dose. In a subset of 12 participants, after the second dose, the geometric mean PRNT₅₀ titre was 27 and the geometric mean PRNT₉₀ titre was 8.4”

    本文局限性：This study did not include data on other potential correlates of protection such as T cells or antibody-dependent cellular cytotoxicity antibody. Future studies could investigate alternative strategies to increase antibody concentrations and clinical protection in recipients of inactivated vaccines, including administration of booster doses. 
    该研究不包括其他潜在的与疫苗保护率相关数据，如 T 细胞免疫或抗体依赖性细胞毒性抗体。 进一步可能会研究如何提高灭活疫苗接受者的抗体滴度，增强临床保护效果，包括加强针。

     该论文第一作者为Wey Wen Lim，通讯作者为Benjamin J Cowling（作者单位WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China）。

参考文献：

Lim W, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative

immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe

2021; published online July 15. https://doi.org/10.1016/S2666-5247(21)00177-4.

原文链接：

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00177-4/fulltext